Valuation: Glaukos Corporation

Market Cap 9.65B 8.58B 8.01B 7.3B 13.76B 928B 13.89B 96.88B 37.54B 474B 36.25B 35.46B 1,523B P/E 2026 *
-203x
P/E 2027 * 516x
Enterprise Value 9.48B 8.42B 7.86B 7.16B 13.51B 911B 13.64B 95.13B 36.86B 466B 35.59B 34.82B 1,495B EV / Sales 2026 *
13.7x
EV / Sales 2027 * 11x
Free-Float
96.38%
Yield 2026 *
-
Yield 2027 * -
1 day+0.36%
1 week+6.04%
Current month-0.27%
1 month-8.79%
3 months+10.39%
6 months+45.21%
Current year+45.03%
1 week 151.71
Extreme 151.71
168.73
1 month 151.01
Extreme 151.01
185.35
Current year 93.96
Extreme 93.96
191.62
1 year 73.16
Extreme 73.16
191.62
3 years 59.22
Extreme 59.22
191.62
5 years 33.33
Extreme 33.33
191.62
10 years 23.08
Extreme 23.075
191.62
Manager TitleAgeSince
Chief Executive Officer 65 2000-12-31
Director of Finance/CFO 56 2022-03-31
President 50 2022-03-31
Director TitleAgeSince
Chairman 65 2021-12-30
Director/Board Member 71 2014-06-30
Director/Board Member 57 2014-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/25/26 Sell

Executive/Senior Manager

-1,615 0.0028%
9/16/26 Sell

Executive/Senior Manager

-1,457 0.0025%
8/28/26 Sell

Executive/Senior Manager

-13,744 0.0240%
Change 5-day change 1-year change 3-year change Capi.($)
+0.36%+6.04%+93.81%+130.31% 9.65B
+0.84%-3.74%-26.69%+1.85% 169B
-0.07%-2.55%-9.53%+11.07% 110B
+0.90%+1.13%-24.83%+0.58% 106B
-1.24%-0.76%-49.04%-12.75% 73.87B
-0.24%+0.69%+0.16%+72.58% 58.98B
-0.86%+2.96%+13.57%+59.50% 51.28B
-0.71%-3.82%-7.72%-31.41% 48.16B
+0.12%-0.17%-18.21%+20.29% 40.84B
-1.01%-1.45%+28.48%-9.72% 32.21B
Average -0.19%+0.01%-0.00%+24.23% 69.98B
Weighted average by Cap. +0.03%-1.03%-14.84%+11.78%

Financials

2026 *2027 *
Net sales 691M 614M 573M 522M 985M 66.43B 994M 6.93B 2.69B 33.96B 2.59B 2.54B 109B 850M 755M 705M 643M 1.21B 81.74B 1.22B 8.53B 3.31B 41.78B 3.19B 3.12B 134B
Net income -51.87M -46.08M -43.01M -39.2M -73.94M -4.99B -74.63M -521M -202M -2.55B -195M -191M -8.18B 19.14M 17.01M 15.87M 14.47M 27.29M 1.84B 27.54M 192M 74.43M 941M 71.86M 70.3M 3.02B
Net Debt -175M -155M -145M -132M -249M -16.81B -252M -1.76B -680M -8.59B -657M -642M -27.58B -273M -242M -226M -206M -389M -26.23B -393M -2.74B -1.06B -13.41B -1.02B -1B -43.03B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
26-10-02 US$163.75 +0.36% 742,806
26-10-01 US$163.17 -0.62% 808,411
26-09-30 US$164.19 +3.56% 947,091
26-09-29 US$158.55 -0.01% 638,201
26-09-28 US$158.56 +2.67% 1,400,531
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
163.75USD
Average target price
198.69USD
Spread / Average Target
+21.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock